Ixabepilone, a novel epothilone analog in the treatment of breast cancer

Autor: Xavier Pivot, Martin Demarchi, Ulrich Stein, Loic Chaigneau, C. Villanueva, Tristan Maurina, Thierry Nguyen, Christophe Borg
Přispěvatelé: Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Saas, Philippe
Jazyk: angličtina
Rok vydání: 2008
Předmět:
Oncology
MESH: Cell Death
Drug Evaluation
Preclinical
chemistry.chemical_compound
0302 clinical medicine
Tumor cell death
Medicine
Pharmacology (medical)
MESH: Animals
Neoplasm Metastasis
MESH: Treatment Outcome
0303 health sciences
Cell Death
Clinical Trials
Phase I as Topic
Molecular Structure
biology
Ixabepilone
General Medicine
Metastatic breast cancer
Tubulin Modulators
3. Good health
Treatment Outcome
030220 oncology & carcinogenesis
MESH: Drug Evaluation
Preclinical
[SDV.IMM]Life Sciences [q-bio]/Immunology
Female
MESH: Clinical Trials
Phase II as Topic
medicine.drug
Programmed cell death
medicine.medical_specialty
Epothilones
[SDV.IMM] Life Sciences [q-bio]/Immunology
education
MESH: Molecular Structure
Antineoplastic Agents
Breast Neoplasms
Epothilone
03 medical and health sciences
Clinical Trials
Phase II as Topic
Breast cancer
Internal medicine
MESH: Tubulin Modulators
Animals
Humans
MESH: Epothilones
030304 developmental biology
Pharmacology
MESH: Humans
business.industry
medicine.disease
MESH: Neoplasm Metastasis
Tubulin
MESH: Clinical Trials
Phase I as Topic
chemistry
biology.protein
MESH: Antineoplastic Agents
business
MESH: Female
MESH: Breast Neoplasms
Zdroj: Expert Opinion on Investigational Drugs
Expert Opinion on Investigational Drugs, Taylor & Francis, 2008, 17 (4), pp.593-9. ⟨10.1517/13543784.17.4.593⟩
ISSN: 1354-3784
1744-7658
DOI: 10.1517/13543784.17.4.593⟩
Popis: International audience; BACKGROUND: Natural epothilones and their analogs promote tumor cell death by binding to tubulin and stabilizing microtubules, causing cell death. Ixabepilone (BMS-247550, Ixempra) is an epothilone analog that optimizes the properties naturally observed with epothilone B. OBJECTIVE: To provide an overview of the results achieved by ixabepilone in metastatic breast cancer. METHODS: A PubMed search was performed to provide an extensive review of all published data on ixabepilone, in addition to all data reported from international congresses, from 2003 to 2007. RESULTS/CONCLUSION: There is a clear need for new agents active against resistant metastatic breast cancer and ixabepilone might be a welcome new compound in this situation.
Databáze: OpenAIRE
Externí odkaz: